XML 47 R20.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Note 12 - Segment Information | 9 Months Ended
--- | ---
Dec. 31, 2019
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 12 . S egment Information As of December 31, 2019 , we had five reportable segments, including the new Biopharmaceutical Development reportable segment that we added as a result of the GPT Acquisition discussed in Note 11. "Significant Transactions": Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, Cold Chain Monitoring, and Cold Chain Packaging. Although we have completed the exit of the Packaging Division, since the exit does not qualify for discontinued operations, we will continue to disclose segment results for comparability purposes. The following tables set forth our segment information:
|  | Three Months Ended December 31, 2019 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Cold Chain Monitoring |  |  | Cold Chain Packaging |  |  | Total |
Revenues (1) |  | $ | 11,619 |  |  | $ | 10,014 |  |  | $ | 5,637 |  |  | $ | 4,156 |  |  | $ | 229 |  |  | $ | 31,655 |
Gross profit (loss) |  | $ | 8,098 |  |  | $ | 6,520 |  |  | $ | (1,294 | ) |  | $ | 1,371 |  |  | $ | (18 | ) |  | $ | 14,677 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (19,880 | )
Loss before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (5,203 | )
|  | Three Months Ended December 31, 2018 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Cold Chain Monitoring |  |  | Cold Chain Packaging |  |  | Total |
Revenues (1) |  | $ | 11,545 |  |  | $ | 9,341 |  |  | $ | -- |  |  | $ | 3,744 |  |  | $ | 2,052 |  |  | $ | 26,682 |
Gross profit |  | $ | 7,876 |  |  | $ | 5,922 |  |  | $ | -- |  |  | $ | 1,575 |  |  | $ | 261 |  |  | $ | 15,634 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (14,686 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 948 |
|  | Nine Months Ended December 31, 2019 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Cold Chain Monitoring |  |  | Cold Chain Packaging |  |  | Total |
Revenues (1) |  | $ | 35,823 |  |  | $ | 28,518 |  |  | $ | 5,637 |  |  | $ | 11,059 |  |  | $ | 2,442 |  |  | $ | 83,479 |
Gross profit (loss) |  | $ | 25,323 |  |  | $ | 18,128 |  |  | $ | (1,294 | ) |  | $ | 3,741 |  |  | $ | 394 |  |  | $ | 46,292 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (42,471 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 3,821 |
|  | Nine Months Ended December 31, 2018 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Cold Chain Monitoring |  |  | Cold Chain Packaging |  |  | Total |
Revenues (1) |  | $ | 34,475 |  |  | $ | 26,776 |  |  | $ | -- |  |  | $ | 9,917 |  |  | $ | 5,521 |  |  | $ | 76,689 |
Gross profit |  | $ | 23,660 |  |  | $ | 16,909 |  |  | $ | -- |  |  | $ | 4,203 |  |  | $ | 530 |  |  | $ | 45,302 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (38,648 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 6,654 |
| ( 1 ) | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
| ( 2 ) | Reconciling items include selling, general and administrative, research and development, legal settlement, impairment of goodwill and long lived assets, and other expenses.
The following table sets forth assets by reportable segment:
|  | December 31, 2019 |  |  | March 31, 2019 |
Sterilization and Disinfection Control |  | $ | 76,493 |  |  | $ | 74,230 |
Instruments |  |  | 32,286 |  |  |  | 30,911 |
Biopharmaceutical Development |  |  | 196,366 |  |  |  | -- |
Cold Chain Monitoring |  |  | 31,022 |  |  |  | 32,179 |
Cold Chain Packaging (a) |  |  | 132 |  |  |  | 1,590 |
Corporate and administrative |  |  | 87,168 |  |  |  | 17,857 |
Total |  | $ | 423,467 |  |  | $ | 156,767 |
(a) | Represents net receivables from Cold Chain Packaging customers. The majority of Cold Chain Packaging's receivables are expected to be collected during the three months ending March 31, 2020.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration